Neuronetics Inc
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pul… Read more
Neuronetics Inc (STIM) - Net Assets
Latest net assets as of September 2025: $31.36 Million USD
Based on the latest financial reports, Neuronetics Inc (STIM) has net assets worth $31.36 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($145.47 Million) and total liabilities ($114.11 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $31.36 Million |
| % of Total Assets | 21.56% |
| Annual Growth Rate | N/A |
| 5-Year Change | 24.74% |
| 10-Year Change | N/A |
| Growth Volatility | 99.89 |
Neuronetics Inc - Net Assets Trend (2016–2024)
This chart illustrates how Neuronetics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Neuronetics Inc (2016–2024)
The table below shows the annual net assets of Neuronetics Inc from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $31.80 Million | -6.99% |
| 2023-12-31 | $34.19 Million | -40.08% |
| 2022-12-31 | $57.06 Million | -33.01% |
| 2021-12-31 | $85.17 Million | +234.11% |
| 2020-12-31 | $25.49 Million | -46.73% |
| 2019-12-31 | $47.85 Million | -32.64% |
| 2018-12-31 | $71.04 Million | +136.88% |
| 2017-12-31 | $-192.65 Million | -8.77% |
| 2016-12-31 | $-177.12 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Neuronetics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 23890200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $557.00K | 2.01% |
| Other Components | $446.94 Million | 1613.15% |
| Total Equity | $27.71 Million | 100.00% |
Neuronetics Inc Competitors by Market Cap
The table below lists competitors of Neuronetics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Deoleo S.A
PINK:SOSCF
|
$47.35 Million |
|
Cayson Acquisition Corp
NASDAQ:CAPNU
|
$47.36 Million |
|
Reeder Teknoloji Sanayi ve Ticaret Anonim Sirketi
IS:REEDR
|
$47.36 Million |
|
Laurion Mineral Exploration Inc
PINK:LMEFF
|
$47.38 Million |
|
Raphas Co. Ltd
KQ:214260
|
$47.33 Million |
|
Byuksan Corp
KO:007210
|
$47.32 Million |
|
Woosu AMS Co.Ltd
KQ:066590
|
$47.31 Million |
|
Jaiprakash Associates Limited
NSE:JPASSOCIAT
|
$47.30 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Neuronetics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 34,190,000 to 27,706,000, a change of -6,484,000 (-19.0%).
- Net loss of 43,708,000 reduced equity.
- Other factors increased equity by 37,224,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-43.71 Million | -157.76% |
| Other Changes | $37.22 Million | +134.35% |
| Total Change | $- | -18.96% |
Book Value vs Market Value Analysis
This analysis compares Neuronetics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.40x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $-15786.45 | $1.23 | x |
| 2017-12-31 | $-17170.41 | $1.23 | x |
| 2018-12-31 | $7.94 | $1.23 | x |
| 2019-12-31 | $2.60 | $1.23 | x |
| 2020-12-31 | $1.35 | $1.23 | x |
| 2021-12-31 | $3.34 | $1.23 | x |
| 2022-12-31 | $2.12 | $1.23 | x |
| 2023-12-31 | $1.19 | $1.23 | x |
| 2024-12-31 | $0.87 | $1.23 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Neuronetics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -157.76%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -58.36%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 5.09x
- Recent ROE (-157.76%) is below the historical average (-61.12%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | -32.82% | 1.38x | 0.00x | $6.48 Million |
| 2017 | 0.00% | -39.72% | 1.04x | 0.00x | $3.21 Million |
| 2018 | -33.92% | -45.66% | 0.45x | 1.65x | $-31.20 Million |
| 2019 | -60.70% | -46.35% | 0.63x | 2.09x | $-33.83 Million |
| 2020 | -107.69% | -55.75% | 0.63x | 3.09x | $-30.00 Million |
| 2021 | -36.62% | -56.39% | 0.39x | 1.66x | $-39.71 Million |
| 2022 | -65.12% | -56.99% | 0.56x | 2.05x | $-42.87 Million |
| 2023 | -88.30% | -42.31% | 0.62x | 3.39x | $-33.61 Million |
| 2024 | -157.76% | -58.36% | 0.53x | 5.09x | $-46.48 Million |
Industry Comparison
This section compares Neuronetics Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Neuronetics Inc (STIM) | $31.36 Million | 0.00% | 3.64x | $47.34 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |